Previous 10 | Next 10 |
Mechelen, Belgium; 6 January 2021, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021. Onno van de Stolpe, CEO, will present on Thursday, January 14 at 15.10 CET (09:10 am EST). T...
The world is awash with liquidity as interest rates remain at historic lows. Cheap liquidity is the fuel that will spark the next buyout bing in smaller cap biotech. A diversified ETF specializing in smaller cap biotechs is the perfect vehicle to capitalize on the trend as detaile...
Mechelen, Belgium and Krakow, Poland – 04 January 2021, 22.01 TIME CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Selvita S.A. (WSE: SLV) announced today that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed. The...
Due to the FDA's rejection of Filgotinib's 200 mg dosage for commercialisation in the US. Galapagos' earnings potential has been hampered severely. Yet, the current net cash position exceeds the company's market capitalization. The pipeline has multiple potentially blockbuster mol...
Mechelen, Belgium; 23 December 2020, 18.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announces that Onno van de Stolpe, CEO of Galapagos, has committed to make a personal €10 million donation to African Parks, a non-profit organization that serves at the front...
Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...
Gainers: Aethlon Medical (AEMD) +47%. Aclaris Therapeutics (ACRS) +32%. Tilray (TLRY) +23%. MiMedx Group (MDXG) +23%. Sio Gene Therapies (SIOX) +21%.Losers: Concord Medical Services Holdings (CCM) -43%. BioLineRx (BLRX) -30%. vTv Therapeutics (VTVT) -22%. Sensus Healthcare (SRTS) -1...
Concord Medical Services Holdings (CCM) -40%.vTv Therapeutics (VTVT) -33% after azeliragon flunks in mid-stage alzheimer’s and diabetes study.BioLineRx (BLRX) -27% despite promising motixafortide data in pancreatic cancer.NanoVibronix (NAOV) -17%.Galapagos (GLPG)...
Following a Type A meeting with FDA discussing complete response letter related to Jyseleca's (filgotinib) marketing application for Rheumatoid Arthritis ((RA)), Gilead Sciences (GILD) and Galapagos (GLPG) have agreed to amend their existing arrangement for the commercialization and deve...
-- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Recei...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...